Trial Profile
An Open-label Evaluation of Drug Interactions, Safety, Tolerability and Efficacy of GW273225 Add-on Treatment of Partial Seizures, Whether or Not Secondarily Generalized
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs GW 273225 (Primary) ; Carbamazepine; Phenytoin; Valproic acid
- Indications Partial epilepsies
- Focus Pharmacokinetics
- Sponsors GSK
- 22 Dec 2007 New trial record.